PRECISE ANALYSIS OF THE STATE HTA PROGRESS IN UKRAINE: RESULTS OF THE 1ST YEAR OF IMPLEMENTATION AND IMPACT

Babenko M.[1], Piniazhko O.[1], Serediuk V.[1], Khmelyovska M.[1], Lobas M.[1], Kahveci R.[2], Kosyachenko K.[3], Komarida O.[4]

1. State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine
2. USAID's SAFEMed, Management Sciences for Health, Ukraine
3. Bogomolets National Medical University, Kyiv, Ukraine
4. Ministry of Health of Ukraine, Kyiv, Ukraine

OBJECTIVES

To provide a structured overview of the company submissions - dossiers for state HTA and conclusions made by HTA Department of State Expert Center (SEC) of MOH of Ukraine to define impact for the healthcare system.

METHOD

We performed descriptive analysis to identify distribution of dossiers and published HTA conclusions by nosologies, diseases and targeted lists with the help of pivot tables.

RESULTS

The approval of the Decree of Cabinet of Ministers of Ukraine №1300 on the approval of state HTA dated 23 December, 2020 and HTA guideline for medicines in Ukraine, provided the procedure for pharmaceutical companies that allowed to submit dossiers to the SEC with the aim of potential inclusion on the National list of essential medicines (NLEM) and/or the nomenclature. As of December 2021, 27 dossiers were submitted to the HTA Department of SEC and 14 conclusions with recommendations for MOH were developed in 2021. The majority of the accepted dossiers concerned treatment of the oncologic diseases (59,3%) followed by respiratory diseases (11,1%) and cardiovascular diseases (7,4%). Other nosologies include diabetes mellitus, mental illness, hepatitis, orphan, infectious and hormonal diseases (figure 1). Most of the dossiers aimed for inclusion of medicines to the nomenclature (59,3%), followed by either of the lists (22,2%) and only NLEM (18,5%). 3 medicines out of all conclusions were recommended for listing on the NLEM or the nomenclature (empagliflozin, tiotropium bromide, triptorelin) and 8 medicines were recommended for MEA, others were not recommended. As of January 2022, 8 medicines were under the negotiation process by the MOH for a possible MEA agreement (figure 2).

Figure 1: Accepted dossiers by nosologies as of December 2021



Figure 2: Impact analysis as of January 2022



CONCLUSIONS

As a result of the work done in the context of state HTA by full procedure, the total of 14 conclusions with recommendations were developed, 8 medicines were recommended for MEA and 2 medicines (empagliflozin, tiotropium bromide) were listed in the NEML due to CMU Decree №1431 dated 31 December, 2021.

REFERENCES

1. HTA Guideline "The state health technology assessment for medicines" approved by the Order of MoH №593 dated 29 March, 2021. https://moz.gov.ua/uploads/5/29631-dn_593_29_03_2021_dod.pdf
2. Decree of Cabinet of Ministers of Ukraine №1300 on the approval of state HTA dated 23 December, 2020 https://zakon.rada.gov.ua/laws/show/1300-2020-п#Text
3. Decree of Cabinet of Ministers of Ukraine №1431 dated 31 December, 2021 https://zakon.rada.gov.ua/laws/show/1431-2021-п#Text